These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 22300020)

  • 1. Liver-based in vitro technologies for drug biotransformation studies - a review.
    Fasinu P; Bouic PJ; Rosenkranz B
    Curr Drug Metab; 2012 Feb; 13(2):215-24. PubMed ID: 22300020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons.
    Brandon EF; Raap CD; Meijerman I; Beijnen JH; Schellens JH
    Toxicol Appl Pharmacol; 2003 Jun; 189(3):233-46. PubMed ID: 12791308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocytes as a tool in drug metabolism, transport and safety evaluations in drug discovery.
    Sahi J; Grepper S; Smith C
    Curr Drug Discov Technol; 2010 Sep; 7(3):188-98. PubMed ID: 20843293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.
    Masimirembwa CM; Bredberg U; Andersson TB
    Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell lines: a tool for in vitro drug metabolism studies.
    Donato MT; Lahoz A; Castell JV; Gómez-Lechón MJ
    Curr Drug Metab; 2008 Jan; 9(1):1-11. PubMed ID: 18220566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development.
    Baranczewski P; Stańczak A; Sundberg K; Svensson R; Wallin A; Jansson J; Garberg P; Postlind H
    Pharmacol Rep; 2006; 58(4):453-72. PubMed ID: 16963792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro methods to study intestinal drug metabolism.
    van de Kerkhof EG; de Graaf IA; Groothuis GM
    Curr Drug Metab; 2007 Oct; 8(7):658-75. PubMed ID: 17979654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
    Yan Z; Caldwell GW
    Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of in vitro preparations for semi-quantitative prediction of in vivo drug metabolism.
    De Graaf IA; Van Meijeren CE; Pektaş F; Koster HJ
    Drug Metab Dispos; 2002 Oct; 30(10):1129-36. PubMed ID: 12228190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Present and future in vitro approaches for drug metabolism.
    Ekins S; Ring BJ; Grace J; McRobie-Belle DJ; Wrighton SA
    J Pharmacol Toxicol Methods; 2000; 44(1):313-24. PubMed ID: 11274898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Metabolism in the Liver.
    Almazroo OA; Miah MK; Venkataramanan R
    Clin Liver Dis; 2017 Feb; 21(1):1-20. PubMed ID: 27842765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of enzymes of drug metabolism.
    Meyer UA
    J Pharmacokinet Biopharm; 1996 Oct; 24(5):449-59. PubMed ID: 9131484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery.
    Prakash C; Sharma R; Gleave M; Nedderman A
    Curr Drug Metab; 2008 Nov; 9(9):952-64. PubMed ID: 18991592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes.
    Rushmore TH; Kong AN
    Curr Drug Metab; 2002 Oct; 3(5):481-90. PubMed ID: 12369894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences.
    Jamis-Dow CA; Klecker RW; Katki AG; Collins JM
    Cancer Chemother Pharmacol; 1995; 36(2):107-14. PubMed ID: 7767945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of drug metabolizing activities in pig hepatocytes for use in bioartificial liver devices: comparison with other hepatic cellular models.
    Donato MT; Castell JV; Gómez-Lechón MJ
    J Hepatol; 1999 Sep; 31(3):542-9. PubMed ID: 10488716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic drug metabolism in cystic fibrosis: recent developments and future directions.
    Kearns GL
    Ann Pharmacother; 1993 Jan; 27(1):74-9. PubMed ID: 8431626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human hepatocytes in primary culture: the choice to investigate drug metabolism in man.
    Gómez-Lechón MJ; Donato MT; Castell JV; Jover R
    Curr Drug Metab; 2004 Oct; 5(5):443-62. PubMed ID: 15544436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xenobiotic metabolism and toxicity in primary monolayer cultures of hepatocytes.
    Holme JA
    NIPH Ann; 1985 Dec; 8(2):49-63. PubMed ID: 3908998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.